Theracort

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Theracort

Property Description
Active Ingredient Hydrocortisone (INN)
Pharmacological Class Corticosteroid (Glucocorticoid)
Common Use Anti-inflammatory and Immunosuppressive
Origin Synthetic derivative of natural cortisol
Typical Forms Cream, Ointment, Tablet, Injection

What Type of Medicine is Theracort and What is it Made Of?

Theracort is a registered trade designation for a pharmaceutical product whose active ingredient is Hydrocortisone (INN). This substance is formally classified as a glucocorticoid, a powerful subclass within the larger corticosteroid group of drugs. Hydrocortisone is a synthetic compound that is chemically modeled after the body's natural stress hormone, cortisol. The medicine is primarily a single-ingredient drug, typically used in the form of a topical cream or ointment under the Theracort name, though the active substance is widely available in other forms. The final preparation is composed of the active Hydrocortisone substance and a non-medicinal base/vehicle (e.g., a lipid-based cream) designed to ensure proper absorption and dermal delivery.


Is Theracort a Topical Cream, a Tablet, or an Injection?

Formulations containing Hydrocortisone are manufactured in a variety of dosage forms to accommodate different patient needs. These include cream, ointment, and lotion for topical (on-the-skin) application, as well as tablets for oral use or injectable solutions for parenteral administration. The choice of dosage form dictates the route of administration, determining whether the medicine acts locally or systemically (throughout the body). Hydrocortisone is utilized extensively across these diverse delivery routes. The availability of the medicine in multiple forms allows for targeting either localized skin issues or broader systemic conditions.


What is the General Purpose of This Glucocorticoid?

The overall purpose of the glucocorticoid Hydrocortisone is to exert potent anti-inflammatory and immunosuppressive properties by modulating the body's defensive responses. This mechanism is clinically recognized for its ability to manage localized irritation. Hydrocortisone is characterized as an essential medicine due to these core properties. This status underscores the drug's role in helping to reduce swelling, calm redness, and alleviate the itching and discomfort associated with inflammatory conditions, such as those caused by minor skin irritations or allergic reactions.

Regulatory References

  1. Topical Corticosteroids - StatPearls - NCBI Bookshelf
  2. WHO Model Lists of Essential Medicines
  3. Hydrocortisone - eEML - Electronic Essential Medicines List

What side effects are possible with Theracort?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient in Theracort, Hydrocortisone, classifies adverse reactions by frequency and the body's organ systems, as documented by regulatory authorities like the FDA and EMA.

Adverse Reaction Scope

Adverse reactions are broadly grouped into systemic effects, resulting from widespread absorption, and local reactions, primarily noted with topical application.

  • Common Reactions may include local application site reactions such as burning, itching, or irritation, as well as systemic effects like increased appetite, gastrointestinal disturbances, and mood changes.
  • Rare Reactions include severe psychiatric reactions, bone density loss (osteoporosis), and manifestations of Cushing's Syndrome.

System-Organ-Class Groupings

Documented effects involve several System-Organ Classes (SOCs):

System-Organ Class Examples of Documented Effects
Skin and Subcutaneous Tissue Skin atrophy (thinning), striae, folliculitis
Endocrine System Suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis
Eye Disorders Glaucoma, cataracts (with prolonged use)

Safety Considerations and Restrictions

Official labeling notes specific safety patterns and constraints. The risk of serious systemic consequences, such as HPA axis suppression, is explicitly associated with long-term exposure. The medicine is formally contraindicated in patients with a known hypersensitivity to the substance and in the presence of systemic fungal infections. Special consideration is also documented for pediatric patients, who may be more susceptible to systemic effects due to higher surface area-to-weight ratios.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived strictly from official government regulatory documents detailing the overdose profile for the active ingredient, Hydrocortisone. The risk of overdose is primarily categorized by exposure duration: acute (single event) or chronic (prolonged high-dose use).

Documented Overdose Manifestations

Chronic overdosage is recognized in official labeling by manifestations such as a Cushingoid state and Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Other documented systemic signs include Hypertension, Hyperglycemia, and fluid/sodium retention. Acute overdose is not typically associated with immediate life-threatening symptoms and management is described as symptomatic and supportive therapy.

Severe Outcomes and Emergency Actions

Chronic over-exposure may lead to severe outcomes including the risk of Adrenal Crisis and Congestive Heart Failure in susceptible patients. Furthermore, severe psychiatric derangements have been documented in official regulatory profiles.

Regulators mandate specific actions in case of a suspected overdose. You should immediately call a Poison Control Helpline for advice. Immediate emergency services must be contacted if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened, as this constitutes a life-threatening situation.

Population-Specific Considerations

Official prescribing information notes that pediatric patients may demonstrate greater susceptibility to systemic toxicity, including HPA axis suppression. Specific signs to monitor in children include linear growth retardation and delayed weight gain.

Therapeutic Uses of Theracort

Quick Facts

  • Relief of Symptoms Associated with Inflammatory Skin Conditions: May be used to manage redness, itching, and swelling.
  • Support for Allergic Rhinitis: Helps address nasal symptoms related to seasonal and year-round allergies.
  • Management of Certain Joint/Tissue Inflammation: Provides short-term support for flare-ups of conditions affecting joints and soft tissues.

Theracort is a prescription medication utilized in therapeutic contexts to help manage inflammation and immune system response in a range of conditions. The primary approved uses involve providing relief from symptoms.

In dermatology, Theracort is indicated for the temporary relief of inflammatory and pruritic manifestations associated with dermatoses that respond to corticosteroid treatment, such as eczema, psoriasis, and various forms of dermatitis. It is not intended to resolve the underlying condition but to help minimize discomfort.

In respiratory care, Theracort is used to help control the nasal symptoms of both seasonal and perennial allergic rhinitis in patients aged six years and older. These symptoms may include sneezing, runny nose, and nasal congestion.

Theracort also has a role in managing musculoskeletal and rheumatic disorders. It may be administered as an adjunct therapy for the short-term management of acute episodes or exacerbations of conditions like acute gouty arthritis, rheumatoid arthritis, and bursitis. This application is intended to help reduce local pain and swelling associated with flare-ups.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Theracort — Official Regulatory Information

Theracort (Triamcinolone) is subject to strict eligibility rules documented in official government regulatory labeling to ensure patient safety and avoid serious adverse reactions.


Populations for whom use is Contraindicated

  • Patients with known hypersensitivity to Triamcinolone or any component of the specific product formulation.
  • Patients with systemic fungal infections (applies to injectable and systemic forms).
  • Intrathecal (into the spinal fluid) or Epidural administration is strictly prohibited for injectable suspensions due to reported serious neurologic events.
  • Patients requiring intramuscular corticosteroid preparations for Idiopathic Thrombocytopenic Purpura (applies to injectable suspension).

Eligibility-Related Restrictions and Conditional Use

Use of Theracort is restricted or requires special caution and monitoring in several groups, including:

  • Patients with ocular herpes simplex (risk of corneal perforation).
  • Patients with latent tuberculosis or gastrointestinal disorders such as diverticulitis.
  • Pediatric patients receiving chronic therapy, who must be monitored closely for growth interference and HPA axis suppression.
  • Neonates if the formulation contains benzyl alcohol as a preservative (risk of severe toxicity).

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Systemic use may cause fetal harm, particularly during the first trimester; use is conditional only if the potential benefit outweighs the potential risk.
  • Lactation: Triamcinolone passes into breast milk, but the secreted quantity is generally not expected to cause a deleterious effect on the infant.

What should I know about interactions with other medicines?

Theracort (a corticosteroid) can interact with several other medications, which may affect its action or increase the risk of side effects. It is essential to inform your healthcare provider about all prescription and non-prescription drugs, vitamins, herbal supplements, and foods you are using.

Medications Affecting Theracort Levels

Theracort is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Drugs that inhibit or induce this enzyme can change the concentration of Theracort in the body:

  • CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, erythromycin, and grapefruit juice) can slow down the breakdown of Theracort, leading to increased levels and a greater risk of corticosteroid-related side effects, such as Cushing’s syndrome and adrenal suppression.
  • CYP3A4 Inducers (e.g., rifampin, phenytoin, phenobarbital, and carbamazepine) can speed up the breakdown of Theracort, potentially reducing its effectiveness.

Increased Risk of Bleeding

Concomitant use of Theracort with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, or with anticoagulants (blood thinners), such as warfarin, significantly increases the risk of gastrointestinal side effects, including bleeding and ulceration. This combination generally requires close monitoring by a healthcare professional.

Drug Type Example Agents Potential Effect Action
CYP3A4 Inhibitors Ketoconazole, Ritonavir Increased Theracort levels May require a Theracort dose reduction
CYP3A4 Inducers Rifampin, Phenytoin Decreased Theracort levels May require a Theracort dose increase
NSAIDs / Anticoagulants Ibuprofen, Warfarin Increased risk of GI bleeding/ulcers Use with caution; monitor closely

Mechanism of Action

Intracellular Receptor Engagement and Gene Modulation

Theracort's mechanism begins by targeting the Glucocorticoid Receptor (GR), which is widely expressed inside various cells, acting as an agonist. This engagement triggers the drug-receptor complex to move to the nucleus, where it alters the cell's gene expression to either inhibit or promote the transcription of genes related to inflammatory and metabolic pathways.

Suppression of Pro-Inflammatory Cascades

The core anti-inflammatory effect is achieved through transrepression, where the drug-receptor complex suppresses the activity of major pro-inflammatory transcription factors like NF-kappaB. This limits the cell's output of inflammatory mediators, such as cytokines and chemokines, resulting in a systemic reduction in immune response activity.

Influence on Metabolic Homeostasis

A secondary effect of GR binding involves transactivation of metabolic genes. This mechanism promotes hepatic gluconeogenesis and protein/fat catabolism, which results in the modulation of circulating glucose levels and systemic resource redistribution.

Dosage and Administration Information

How to Use Theracort

The usage of Hydrocortisone (the active ingredient in Theracort) is determined by its formulation and the administration route.

Official Routes and Dosing

Hydrocortisone is administered through multiple approved routes, each with specific dosing instructions:

  • Oral: Tablets (5 mg, 10 mg, or 20 mg strengths) are typically used for systemic conditions. The initial daily dosage may range from 20 mg to 240 mg, with the dose adjusted to the lowest effective level.
  • Intravenous (IV) / Intramuscular (IM): The sterile powder for injection is used for systemic needs when oral therapy is not feasible. The initial dose for acute or severe conditions is typically 100 mg to 500 mg, which may be repeated at intervals of 2, 4, or 6 hours based on clinical response. The IV route is preferred for initial emergency use.
  • Topical: Creams and ointments are applied to the affected area as a thin film 2 to 4 times daily.

Administration Requirements

Adherence to the following instructions is required for proper use:

Administration Aspect Official Requirement
Oral Intake Tablets should be taken with or after food or milk to reduce the risk of stomach irritation.
Injection Preparation The sterile powder must be reconstituted with a suitable diluent (e.g., Bacteriostatic Water for Injection) before administration.
Topical Application The treated area should not be bandaged or covered (occlusive dressing) unless specifically directed by a healthcare provider.
Long-Term Use If the drug is taken for a prolonged period, the dose is to be gradually withdrawn (tapered) rather than stopped abruptly.
Pediatrics For children, parenteral dosage is based more on the severity of the condition than on body weight, but should not be less than 25 mg daily in acute cases.

These instructions govern how the drug is prepared, taken, applied, and eventually discontinued to ensure standardized and consistent administration practices.

Recent Clinical Evidence

Research evidence / Overview of studies for Theracort


Evidence for Use in Inflammatory Skin Conditions (Dermatoses)

Research for the topical formulation of Hydrocortisone, the active compound in Theracort, was explored in short-term, randomized controlled trials (RCTs) for its use in inflammatory skin conditions. These studies were used in research exploring how symptoms change over time by comparing the medicine to an inactive vehicle or to other similar agents. Researchers focused on outcomes linked to inflammatory or irritative states, such as changes in objective disease severity scores and patient-reported outcomes describing perceived discomfort.

Findings indicate that, in the short term, studies reported changes in scores on disease severity and itch scales. Studies monitored how the appearance of redness and swelling evolved during the initial treatment weeks. However, long-term effects are not fully established. Clinical trials had follow-up durations that were limited, meaning there is limited information regarding the durability of symptom modulation after the initial period.


Research Evidence for Acute Symptom Management in Allergic Rhinitis

The research for using Hydrocortisone to address nasal symptoms was evaluated in various contexts, including systematic reviews which often explored the performance of the intranasal corticosteroid (INCS) drug class as a whole. The studies monitored outcomes capturing phases of heightened symptom activity, such as changes in sneezing, congestion, and discharge, and outcomes reflecting daily functioning.

Data show patterns related to symptomatic change across the INCS drug class. The evidence is generally consistent in describing these patterns. For very acute episodes, the systemic form was observed in some studies where it reported measurements of rapid, short-term symptom suppression. Comparative evidence is lacking for Hydrocortisone nasal spray specifically, and the subgroup findings are uncertain when comparing it directly to other similar nasal treatments.


Evidence for Acute Episodes in Musculoskeletal and Joint Flares

Hydrocortisone was studied for its role in managing the acute manifestations of conditions like rheumatoid arthritis and gouty arthritis. Research included randomized controlled trials (RCTs) that explored outcomes describing episodic or acute changes. Studies conducted during periods of increased symptom activity reported observations of rapid symptomatic change in pain and inflammation markers during the initial short-term period.

However, findings report how symptoms evolved in the observed populations, noting that the magnitude of reported change decreased significantly after the initial three months. Evidence quality varies across studies, and the long-term effects are not fully established for maintaining symptom modulation in chronic conditions.

Key Studies & References

  1. WHO Model List of Essential Medicines - Hydrocortisone

Frequently Asked Questions (FAQ)

Common questions about Theracort (FAQ)

Q: What is Theracort used for besides the main condition?

Hydrocortisone, the active ingredient in Theracort, is officially approved for a broad range of indications beyond its main use. These generally include certain endocrine disorders, various rheumatic disorders, and conditions involving serious allergic states where anti-inflammatory action is required.


Q: How quickly should I expect Theracort to start working?

Official literature describes the onset of action (how quickly it starts to work) as depending on the form of the medicine used. A rapid effect is often observed following intravenous injection for very acute scenarios, though individual experiences may vary.


Q: Can Theracort affect my sleep?

According to the official adverse reaction profile, insomnia (difficulty falling or staying asleep) is listed as one of the documented psychiatric or nervous system effects. This effect is included in the wider set of reported mood changes.


Q: Are there any common foods or drinks that interact with Theracort?

Official prescribing information indicates that certain foods and drinks, notably grapefruit juice, and some medications can affect an enzyme in the liver called CYP3A4, which processes Theracort. Changes to this enzyme's activity can alter how much medicine stays in your body. Official sources note the importance of discussing all foods, drinks, and supplements with a healthcare provider.


Q: Does Theracort cause weight gain?

Weight gain is documented as a possible effect in official information, often related to changes in fluid balance in the body. The mechanism is associated with sodium retention, fluid accumulation, and also increased appetite noted in the adverse reaction profile.


Q: Is Theracort safe for long-term use?

According to regulatory documents, the long-term exposure to high amounts of the medicine is associated with a risk of serious systemic effects. These documented risks include the possibility of HPA axis suppression (where the body's natural hormone production is disrupted), loss of bone density, and the formation of cataracts.


Q: Why do some people experience headaches with Theracort?

The official adverse reaction profile includes headache as one of the documented neurological effects. Like all documented side effects, the frequency of occurrence can vary between individuals.


Q: Can I take Theracort if I have a history of liver problems?

Official regulatory documents advise that use requires caution in patients who have pre-existing liver conditions, such as cirrhosis. This is because the body's clearance of the medicine may be decreased, potentially leading to an enhanced effect that requires monitoring.


Q: What are the most common side effects listed for Theracort?

The most frequently documented systemic reactions listed in the adverse event profile include changes like increased appetite, fluid retention which may cause swelling, and gastrointestinal disturbances. Mood changes are also commonly reported.


Q: Is it normal to feel a bit restless after starting Theracort?

Official documents list restlessness as one of the documented psychiatric or nervous system effects that may be associated with the medicine's use. Other effects, such as mood swings, are also noted in the adverse reaction profile.


Q: Are there any special warnings for older adults using Theracort?

While there is no dedicated special warning section only for older adults, regulatory precautions for conditions such as osteoporosis, fluid retention, and hypertension are considered relevant to this population. These precautions advise close monitoring by a healthcare provider.


Q: Can Theracort impact the results of laboratory tests?

Official information notes that the medicine has the potential to interfere with the results of certain laboratory tests. For example, it may cause falsely elevated cortisol results in some tests due to a mechanism called cross-reactivity.


Q: What happens if I forget to take a dose of Theracort?

According to official regulatory guidance, if a dose is missed, the guidance is to take it as soon as possible. However, if it is almost time for the next scheduled dose, the regulatory guidance states that the missed dose should be skipped and the normal schedule resumed.


Q: How long does Theracort stay in your system?

The elimination half-life, which describes the time it takes for the body to reduce the amount of medicine by half, is detailed in the official pharmacokinetic profile. This profile provides factual data on how the medicine is absorbed, distributed, and cleared from the body.


Q: Is Theracort addictive or habit-forming?

Official information does not describe the medicine as addictive, but it may cause the body to become dependent on it for hormone supply (adrenal suppression). Because of this potential dependence, regulatory guidance notes the need for the dose to be gradually reduced (tapered) when stopping the medicine.


Q: Can children or teenagers use Theracort?

Official labeling states that the use of this medicine in children and teenagers should be closely monitored by a healthcare provider. They may be more susceptible to systemic effects, including potential interference with growth and disruption of the natural hormone system (HPA axis suppression).


Q: Is there a risk of withdrawal symptoms when stopping Theracort?

Abruptly stopping the medicine after a period of prolonged use can lead to a condition known as drug-induced secondary adrenocortical insufficiency. Official documents describe that this situation necessitates the dose be gradually reduced (tapered).


Q: Is it okay to drive while taking Theracort?

Regulatory documents address the medicine's potential effect on the ability to drive and operate machinery. This assessment is based on the known psychiatric or neurological effects, such as dizziness or mood changes, documented in the safety profile.


Q: Does Theracort cause dry mouth?

Dry mouth is documented in the official adverse reaction profile of the medicine. Its specific frequency of occurrence, however, is not commonly reported.


Q: Can I use Theracort if I am taking supplements?

The official drug label states the importance of discussing all substances being taken, including prescription drugs, non-prescription products, vitamins, and herbal supplements. This discussion is needed due to the potential for interactions that could alter how Theracort works.


Q: What if I take too much Theracort?

The official safety information notes that taking excessively high doses over a chronic period can lead to signs of Cushing's syndrome and other serious effects related to systemic corticosteroid exposure. Official information describes that these effects may be managed by adjusting the dosage or ceasing the medicine.


Q: Is Theracort known to cause anxiety or mood changes?

The adverse reaction profile includes various documented psychiatric effects. These include feelings of anxiety, euphoria, and changes such as mood swings and difficulty sleeping (insomnia).


Q: What is the full list of ingredients in Theracort?

The final product contains the active ingredient, Hydrocortisone, and a complete list of non-medicinal components (often called inactive ingredients). The full list of these components is available in the official regulatory documentation, such as the package insert for your specific formulation.


Q: Is there a maximum time someone can take Theracort?

The appropriate duration of therapy is determined based on the patient's specific condition and the associated risk/benefit assessment. For certain acute, high-dose intravenous uses, official guidance describes that continuation is generally limited to 48 to 72 hours.


Q: What is the shelf life of Theracort?

The unopened medicine's shelf life is indicated by the expiration date stamped on the container. Additionally, official regulatory instructions for some liquid formulations define a limited use period (e.g., 60 or 120 days) after opening the bottle.


Q: Can Theracort be used by people with kidney disease?

Official information notes that use is a consideration for patients with a history of renal insufficiency (kidney disease). This is due to the potential for the medicine to cause sodium retention and associated fluid accumulation.


Q: Will Theracort affect my ability to get pregnant?

According to official regulatory information, there is no evidence suggesting that the medicine affects fertility or the ability to get pregnant in either men or women.


Q: Are there any black box warnings associated with Theracort?

The official labeling for Theracort does not include a Black Box Warning (BBW). However, it does contain important Warnings and Precautions regarding significant risks such as increased susceptibility to infection and the potential for adrenal suppression.

How should Theracort be stored and disposed of?

How to Store and Dispose of Theracort?

The storage and disposal of Theracort (Hydrocortisone) must strictly follow the requirements documented in official regulatory labeling to ensure product integrity and public safety.

Official Storage Requirements

Requirement Regulatory Standard
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Handling Protect from freezing. The container must be kept tightly closed and stored in a dry place.
Protection Keep this and all medications out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired medication, it is mandatory to consult a pharmacist or use a formal drug take-back program. Regulatory guidance prohibits disposal by flushing down a toilet or pouring down a drain. The medicine must not be placed in household trash unless proper deactivation steps are followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Theracort found in:

A-Z Index: